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Abstract
Nipah virus (NiV) is a member of the genus Henipavirus (family Paramyxoviridae) that causes severe and often lethal
respiratory illness and encephalitis in humans with high mortality rates (up to 92%). NiV can cause Acute Lung Injury (ALI) in
humans, and human-to-human transmission has been observed in recent outbreaks of NiV. While the exact route of
transmission to humans is not known, we have previously shown that NiV can efficiently infect human respiratory epithelial
cells. The molecular mechanisms of NiV-associated ALI in the human respiratory tract are unknown. Thus, there is an urgent
need for models of henipavirus infection of the human respiratory tract to study the pathogenesis and understand the host
responses. Here, we describe a novel human lung xenograft model in mice to study the pathogenesis of NiV. Following
transplantation, human fetal lung xenografts rapidly graft and develop mature structures of adult lungs including cartilage,
vascular vessels, ciliated pseudostratified columnar epithelium, and primitive ‘‘air’’ spaces filled with mucus and lined by
cuboidal to flat epithelium. Following infection, NiV grows to high titers (107 TCID50/gram lung tissue) as early as 3 days post
infection (pi). NiV targets both the endothelium as well as respiratory epithelium in the human lung tissues, and results in
syncytia formation. NiV infection in the human lung results in the production of several cytokines and chemokines including
IL-6, IP-10, eotaxin, G-CSF and GM-CSF on days 5 and 7 pi. In conclusion, this study demonstrates that NiV can replicate to
high titers in a novel in vivo model of the human respiratory tract, resulting in a robust inflammatory response, which is
known to be associated with ALI. This model will facilitate progress in the fundamental understanding of henipavirus
pathogenesis and virus-host interactions; it will also provide biologically relevant models for other respiratory viruses.
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Introduction
Nipah virus (NiV) is a member of the genus Henipavirus (family
Paramyxoviridae) that causes severe and often lethal respiratory
illness and encephalitis in humans resulting in case fatality rates of
up to 92% [1]. The first human cases of NiV infection were
identified during an outbreak of severe febrile encephalitis in
Malaysia and Singapore in 1998–1999 [2,3]. More recently,
outbreaks have occurred in Bangladesh and India almost yearly
since 2001 [1,4]. NiV can cause Acute Lung Injury (ALI) in
humans, and human-to-human transmission has been observed in
recent outbreaks of NiV [5,6,7]. Data on the histopathology of the
lungs of NiV cases is limited to necropsy findings in the respiratory
tract of NiV infected cases and include hemorrhage, necrosis and
inflammation in the epithelium of the small airways but not in the
bronchi [8].
Endothelial cells have been identified as a major target for NiV
and most studies have focused on the role of the endothelium in
NiV pathogenesis [9,10,11]. However very limited data is
available on the host responses following NiV infection in the
human lung. While the endothelium plays an important role in the
terminal stages of NiV infection, the role of the respiratory
epithelium in the early stages of infection is critical; however, it
remains largely unexplored. The specific sites of henipavirus
infection in the human respiratory tract are still unknown as well
as the molecular mechanism by which these viruses cause disease
in humans. We have previously shown that NiV can efficiently
infect human respiratory epithelial cells from the trachea, bronchi
and small airways resulting in the induction of key inflammatory
mediators that have been implicated in leukocyte recruitment and
ALI [12]. Similarly, in animal models (hamster, ferret and African
green monkey), NiV can replicate to high titers in the lungs of
these animals and cause acute and severe respiratory distress
[13,14,15,16,17]. Human xenograft mouse models have previous-
ly been used to study tissue development and cancer as well as the
pathogenesis of infectious agents [18,19,20]. The majority of viral
pathogenesis studies involving human xenograft mice focus on
Human Immunodeficiency Virus (HIV) or Human Cytomegalo-
virus (HCMV) in humanized mice that have been grafted with
human hematopoietic stem cells and thymus [21,22].Here we
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report the first characterization of NiV infection of the human
respiratory tract using a human lung xenograft model to gain
further insight into the mechanisms of NiV pathogenesis in
humans. Our results showed that NiV replicates to high titers in
the human lung and that infection results in the induction of a
robust host response.
Results
Human lung xenograft development
Severely immunodeficient NSG mice served as hosts to support
the successful engraftment of human lung xenografts. We
implanted 6 small fragments of human fetal lung in the dorsal
subcutaneous space, 3 on each side of the spine. Following
transplantation, human fetal lung xenografts typically increased in
size by 2–10 fold over 3 months. The human fetal lung xenografts
rapidly grafted and developed mature structures similar to those
seen in adult lung (Figure 1A). These mature structures included
bronchi that were partially surrounded by cartilage (Figure 1B),
lined with ciliated pseudostratified columnar epithelium
(Figure 1C) and surrounded by longitudinal elastic fibers. The
bronchi divide into bronchioles and terminal bronchioles lined by
cuboidal to flat epithelium (Figure 1D). The distal respiratory tract
comprises of primitive alveolar spaces that are lined with both cells
that have flat (type 1) and larger rounded (type 2) pneumocyte
morphology (Figure 1E). The alveolar walls of xenografts were
thicker than those of normal adult human lungs. The human graft
was well vascularized with the presence of arteries, veins, and
capillaries (Figure 1F). Finally, the expression patterns of ephrin
B2, the receptor of NiV, was similar to that seen in normal human
lung tissue [23] (Figure 1G) with expression on bronchial
epithelium, alveolar cells and vasculatures (Figure 1H).
NiV replication in human lung xenografts
Natural NiV infection involves exposure to the virus through the
respiratory epithelium. To mimic this route in human lung
xenografts that lack air exchange, tissues were directly injected
with NiV. Following direct intragraft injection of the 3 lung tissues
on the left side (primary infection) within each mouse, NSG mice
did not show any signs of morbidity or mortality during our
observation period of 10 days. In addition, two non-grafted NSG
mice that were challenged intradermally as controls, with the same
dose as xenografts, did not develop any clinical signs. Primary
infection of the human lung xenografts resulted in detection of
infectious NiV as early as 1 day post infection (Figure 2A) and NiV
replicated to high titers (107 TCID50/gram tissue) by day 3 post
infection. NiV titers remained high until the end of the experiment
at 10 days post infection. Importantly, high titers of NiV were also
detected in the other 3 lung tissues (on the right side of each mouse)
that were not initially infected through direct intragraft injection as
early as 3 days post infection. This finding clearly demonstrates that
the virus can spread from infected human lung grafts to uninfected
grafts in the same mouse, most likely through viremia (secondary
infection; Figure 2A). The presence of viremia was further
supported by the observation that infectious NiV was detected,
albeit at lower levels, in several mouse tissues including lung, brain,
heart, spleen and kidney at various time points post infection
(Figure 2B). In fact, viremia was detected in a blood sample of 1
animal on day 10 post infection in which a low level (300 TCID50/
mL) of infectious NiV was determined (Table 1). Interestingly, virus
was not detected in organs from non-grafted NSG mice that were
challenged intradermally with the same dose (Table 1), suggesting
the NSG mouse tissues are probably not intrinsically susceptible to
NiV. In order to confirm that the human lung xenografts could be
infected via the hematogenous route, we next challenged 2 lung-
engrafted NSG mice with NiV via the IP route. The IP challenge
with NiV in this model confirmed that infection resulted in
detectable viremia in 1 animal with virus spreading to the human
lung xenografts in both, replicating to high titers and resulting in
histopathological changes similar to those observed with intragraft
challenge (Table 1). Together, these data suggest that following
intragraft infection, the human lung is highly susceptible to NiV
infection and results in viremia and subsequent spread to other
organs in the absence of disease.
NiV induced histopathology in human lung xenografts
In order to study the histopathological changes associated with
NiV infection in the human lung, tissue sections were stained with
hematoxylin and eosin (H&E). No gross pathologic lesions were
observed in the human lung grafts. Since NSG mice exhibit
multiple defects in innate and adaptive immunity [24], NiV
infection in human lung grafts did not result in significant
inflammation. Histopathological changes in the human lung
tissues following NiV infection were independent of the route of
infection (intragraft, indirect or intraperitoneal) and included small
focal areas with syncytia and necrosis as early as day 3 pi
(Figure 3A). These areas rapidly expanded to large areas with
hemorrhages and significant loss of architecture of the small
airways by day 10 pi (Figure 3B). The main histopathological
features of NiV infection in these tissues were the characteristic
syncytia formation (Figure 3C) and areas of necrosis (Figure 3D).
Syncytia formation could be observed in bronchial epithelium
(Figure 3C), alveolar epithelium (Figure 3E) and vascular
endothelium (Figure 3F). In addition, fibrinoid necrosis was
observed in some of the vasculature as well as recruitment of
granulocytes (Figure 3F). In agreement with the absence of clinical
signs, NiV infection did not result in histopathological changes in
any visceral mouse tissue (Table 1).
NiV tropism in human lung xenografts
In order to identify the cells targeted by NiV in the human lung,
viral nucleocapsid protein (N) expression in human lung grafts was
examined with immunohistochemistry. Expression of NiV N
Author Summary
Nipah virus (NiV) is a highly pathogenic zoonotic virus that
causes fatal disease in humans and a variety of other
mammalian hosts including pigs. Given the lack of
effective therapeutics and vaccines, this virus is considered
a public health and agricultural concern, and listed as
category C priority pathogen for biodefense research by
the National Institute of Allergy and Infectious Diseases.
Both animal-to-human and human-to-human transmission
has been observed. Studies on the molecular mechanisms
of NiV-mediated pathogenesis have been hampered by
the lack of biologically relevant in vivo models for studying
the initial host responses to NiV infection in the human
lung. We show here a new small animal model in which we
transplant human lung tissue for studying the pathogen-
esis of NiV. We showed that NiV can replicate to high levels
in the human lung. NiV causes extensive damage to the
lung tissue and induces important regulators of the
inflammatory response. This study is the first to use a
human lung transplant for studying infectious diseases, a
powerful model for studying the pathogenesis of NiV
infection, and will open up new possibilities for studying
virus-host interactions.
Nipah Virus Infection in Human Lung
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Figure 1. Histological characterization of human lung xenografts. Normal (A) and xenograft (B–F) human lung sections were stained with
H&E as described in Experimental Procedures. Following transplantation, human lung xenografts develop mature structures (B) similar to those seen
in normal human lung (A)(106magnification). Structures include pseudostratified ciliated epithelium (C) (406magnification), terminal bronchioles
(D) (106 magnification), alveolar spaces (E)(406 magnification) and pulmonary vasculature (F)(106 magnification). Ephrin B2 expression was
observed in normal human lung (red) (G) and human lung xenograft tissues (yellow) (H) with similar distribution on epithelium (106magnification).
Br = bronchi, V =pulmonary vasculature, Av= alveoli, Ca = cartilage, Ci = cilia, Pe = pseudostratified epithelium, Ef = elastic fibers, Tb= terminal
bronchiole.
doi:10.1371/journal.ppat.1004063.g001
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coincided with the focal areas of histopathological changes on day
3 pi and showed intense staining (Figure 4A). By day 10,
widespread expression of NiV N was observed throughout the
human lung tissues (Figure 4B). NiV primarily targeted the
respiratory epithelium of the bronchi and bronchioles, interstitial
mesenchymal cells (Figure 4C), and the small airways (Figure 4D).
Cells targeted in the small airways were primarily cuboidal, which
is consistent with type-2 pneumocyte morphology, although cells
with type-1 pneumocyte morphology also showed reactivity. In
addition to the respiratory epithelium, NiV replication also
involved the vasculature (Figure 4E). In agreement with the
observation that low levels of infectious virus were detectable in
several mouse tissues, small focal areas of viral antigen primarily
focused in small airway epithelium could be detected in mouse
lungs (Figure 4F) but not in other organs tested (Table 1). Tropism
of viral antigen in mouse lung was similar between tissues infected
by direct injection or following IP challenge (data not shown).
Although focal areas were generally not centered around vessels
(Figure 5A) during the early stages of infection, when NiV
infection involved the vasculature, CD31-positive endothelial cells
were a specific target of infection (Figure 5B). Similar findings were
observed in animals challenged via the IP route (Table 1).
Inflammatory responses during NiV infection
In order to elucidate the host responses following NiV infection
in the human lung, the expression of several cytokines and
chemokines was determined in homogenates of human lung
xenografts following direct infection with NiV (Figure 6). Since
human immune cells were absent in this model, any expression of
human cytokines or chemokines was primarily the result from NiV
infection of human epithelial and endothelial cells. NiV infection
in human lung resulted in the expression of several cytokines/
chemokines, including eotaxin-1, G-CSF, GM-CSF, TNFa,
VEGF, IP-10, IL-1b and IL-6 starting by day 5 pi (Figure 6).
Expression of GM-CSF, TNFa, IP10 and IL-1b peaked on day 5
post infection and gradually declined over time. IL-6 and eotaxin-
1 expression peaked at day 7 pi, whereas G-CSF initially peaked
on day 5 but remained high throughout infection. Interestingly,
VEGF expression continued to increase over time concomitant
with the increased hemorrhaging and remodeling of the lung. The
cytokine and chemokines profiles were similar between lung
xenografts following primary (direct) or secondary (indirect)
infection (data not shown).
Discussion
Nipah virus is an emerging zoonotic virus that can cause severe
respiratory distress and encephalitis in humans [1]. Despite
intensive studies in vitro and in animal models, little is known
Figure 2. Nipah virus replication in human lung xenografts.
Virus replication was determined in human lung (A) and mouse (B)
tissues at days 1, 3, 5, 7 and 10 post infection by virus titration. Titers
were determined in human lung following primary (direct injection) or
secondary (infection due to viremia). Samples from three animals were
assayed and analyzed and the mean titers were calculated as TCID50/
gram tissue. The error bars represent the standard deviation.
doi:10.1371/journal.ppat.1004063.g002
Table 1. Summary of virological and histological findings in human lung graft, mouse tissues and blood following Nipah virus
challenge.
Route of infection Human lung Mouse tissue
Infectious Virus Viral Antigen Histopathology Infectious Virus Viral Antigen Histopathology Blood
Direct (n=15;
Primary)
+++ +++ +++
Indirect (n=9;
Secondary)
+++ +++ +++ + +; starting 5DPI in lung 2 +
IP* (n =2) +++ +++ +++ + +; in lung 2 +
SC# (n = 2) N/A N/A N/A 2 2 2 2
N/A=Not applicable. Direct = injection into the graft, resulting in primary infection; Indirect = secondary infection resulting from virus dissemination from the direct
infected lung graft. IP = Intraperitoneal challenge. SC = Subcutaneous challenge. Infectious virus was determined in human lung and mouse tiisues and whole blood by
TCID50% as described in Materials & Methods. Viral antigen was detected with an anti N antibody as described in Materials & Methods. Histopathology is based on H&E
stained lung sections described in Materials & Methods.
* = data available on day 10 post infection only.
#= for control NSG mice only.
+++=high virus titer/intense immunostaining/extensive histopathological changes. += low virus titer/low intensity immunostaining, 2=not detected.
doi:10.1371/journal.ppat.1004063.t001
Nipah Virus Infection in Human Lung
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about the mechanisms governing the development of NiV-related
respiratory disease in humans; this is due to difficulties in obtaining
human samples where the disease is endemic. To address this
important limitation, the goal of the present study was to
characterize a novel human lung xenograft model to study the
pathogenesis of NiV infection in human lung in vivo.
Studies on the molecular mechanisms of NiV-mediated
pathogenesis have been hampered by the lack of biologically
relevant in vitro models for studying the initial host responses to
NiV infection in the human lung [7,13,15]. To fill this gap, we
recently showed that NiV can efficiently replicate in primary
epithelial cells from the human respiratory tract [12]. While this is
an attractive model to study the early steps of NiV entry in the
host, it lacks the complexity of the microenvironment in the lung.
In the current model, we show that human fetal lung tissues
grafted on an immunocompromised mouse develop into more
mature human lung tissues within 3 months after implantation.
Transplanted lung tissues rapidly vascularized and developed
bronchioles, lined with columnar epithelium, and alveolar-like
spaces closely resembling those seen in normal human lung tissue.
The prototype strain of NiV (Malaysia) was used in this study.
While the outbreaks in Malaysia and Singapore have primarily
been associated with the development of severe febrile encephalitis
with a case fatality rate of 38%, respiratory symptoms were
observed (40% of lethal cases) [8]. Interestingly, the more recent
outbreaks in Bangladesh and India are associated with a higher
prevalence of respiratory disease as well as a significantly higher
case fatality rate of 67% to 92% [1,6]. It is currently unknown
Figure 3. Histopathological changes during Nipah virus infection in human lung xenografts. Human lung sections were stained with H&E
as described in Experimental Procedures. (A) Human lung with focal areas of necrosis and syncytia formation (black arrow) on day 3 post infection
(106magnification). (B) Human lung with extensive areas of necrosis, syncytia formation and loss of architecture on day 10 post infection (106
magnification). (C) Bronchi with syncytia formation (*) on day 3 post infection (206magnification). (D) Loss of alveolar architecture and areas of
necrosis (black arrow) on day 10 post infection (206magnification). (E) Alveolar space with syncytial formation (*) on day 3 post infection (406
magnification). (F) Pulmonary vasculature with syncytial formation (*) on day 3 post infection (406magnification), fibrinoid necrosis of the intima,
and influx of granulocytes (black arrowhead). Data are representative from 6 tissues per animal, 3 animals per time point.
doi:10.1371/journal.ppat.1004063.g003
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whether differences in respiratory involvement are due to genetic
difference between the Malaysia and Bangladesh strains of NiV or
whether confounding factors are involved, however both NiV
strains can replicate efficiently and cause respiratory distress in
animals [25,26]. In addition, no histopathological data is available
for human cases of the Bangladesh strain of NiV; therefore, the
Malaysia strain was used in this study to allow for comparisons of
histopathology and viral tropism. In humans, vasculitis and
fibrinoid necrosis in the lungs was observed in the majority of
fatal cases of NiV infection [8]. Multinucleated giant cells were
occasionally observed in alveolar spaces and showed prominent
immunostaining for viral antigen, along with alveolar hemorrhage,
edema and pneumonia. Bronchial epithelium rarely showed
histopathological changes. Nipah viral antigen could also be
observed in the vasculature and rarely in bronchiolar epithelium
[8]. We believe that the lack of viral antigen in the bronchial
epithelium in fatal human cases is most likely due to timing of
sampling. We previously showed, using a hamster model, that the
bronchial epithelium is initially targeted by NiV early on during
infection followed by rapid spread to the interstitium and
involvement of pulmonary vessels [13].
In the present model, NiV replicated to high titers following
intragraft injection, and virus was found to primarily replicate in
respiratory epithelium of the bronchi and small airways. This is
consistent with our previous finding that human respiratory
epithelium is highly susceptible to NiV infection [12]. In animal
Figure 4. Nipah virus tropism in human lung xenografts. Lung sections were stained by immunohistochemical (IHC) detection of Nipah virus
nucleoprotein as described in Experimental Procedures. An overview of viral antigen distribution is shown on day 3 (A) and day 10(B) post infection
(106magnification). (C) Bronchial epithelium positive for NiV antigen in a syncytium (black arrow) on day 3 post infection (406magnification). (D)
Alveolar space with NiV positive cell, primarily cuboidal morphology on day 3 post infection (406magnification). (E) Pulmonary vasculature positive
for NiV antigen on day 3 post infection (406magnification). (F) Small focal area in mouse lung tissue positive for NiV antigen (red) on day 10 post
infection (106 magnification)(nuclei in blue). Br = bronchi, V = pulmonary vasculature. T2 = Type 2 pneumocyte. Data are representative from 3
animals per time point.
doi:10.1371/journal.ppat.1004063.g004
Nipah Virus Infection in Human Lung
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models, the lung is the primary target organ of NiV infection
following intranasal challenge [13,14]. In addition to the
respiratory epithelium, NiV replication was also found in the
endothelium, a type of cell that has been identified as an important
target for NiV [11]. The infection of the vascular system is thought
to occur in the late stages of disease and lead to systemic spread of
these viruses to other organs, including brain and kidney [13,27].
In our model, systemic spread of the virus was indicated by similar
titers and replication kinetics of NiV in directly inoculated lung
grafts and grafts not directly injected with virus. This suggests that
following infection of the lung, NiV quickly becomes viremic and
spreads to other organs. In addition, systemic infection through
intraperitoneal injection with NiV also resulted in infection of the
human lung grafts, thus confirming hematogenous spread of the
virus.
Interestingly, NiV infection in NSG mice engrafted with human
lung tissues did not result in clinical signs despite evidence of
replication in mouse organs, including lung and brain. Previous
studies have shown that NiV infection in type I IFN receptor
knock-out mice and aged mice is lethal [28,29]. Aged mice have
Figure 5. Cell tropism of Nipah virus in human lung xenografts. Lung sections were stained by immunofluorescent detection of Nipah virus
nucleoprotein (red), CD31 (green) and nucleus (blue) as described in Experimental Procedures. (A) Human lung showing focal area of Nipah virus
distinct from pulmonary vasculature on day 3 post infection (106magnification). (B) CD31 positive endothelium of pulmonary vasculature is positive
for Nipah virus antigen (406magnification). Data are representative from 3 animals per time point.
doi:10.1371/journal.ppat.1004063.g005
Nipah Virus Infection in Human Lung
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been shown to mount an aberrant IFN response [30]. While the
NSG mice are immunocompromised, they can mount an IFN
response, which seems sufficient to protect against lethal disease in
our studies. Alternatively, it is possible that NSG mice are not
susceptible to NiV and that the virus measured in mouse organs is
only found in the blood. Also, the small foci of viral antigen
detected in mouse lungs could correspond to emboli of infected
human cells that slough off from the infected grafts.
Several cytokines and especially IL-6, IP-10 and VEGF were
upregulated during NiV infection in the human lung. Interestingly,
the levels of cytokines observed in our xenograft lung model are
similar to those observed in the lungs of fatal cases of influenza virus
A (H1N1) [31]. Upregulation of inflammatory mediators such as
TNF-a, IP-10, IL-1b and IL-6 in the lungs was previously shown to
play a role in the pathogenesis of lethal NiV in hamsters [13], as well
as in the development of ALI with other respiratory virus infections,
including SARS-CoV and influenza virus (H5N1) [30,32,33].
VEGF has an important role in ALI pathogenesis by acting as a
growth factor and increasing vascular permeability [34]. We
previously showed that VEGF is expressed by human respiratory
epithelial cells during NiV infection [12]. This suggests that VEGF
may be partly responsible for the increased pulmonary hemorrhage,
endothelial destruction, and alveolar remodeling in an emphysema-
like phenotype as observed in our model. Since these inflammatory
mediators also play an important role in the recruitment of immune
cell, our data suggests that inflammation could be observed in this
model when human immune cells are present.
In addition to implanting human lung xenografts, the NSG mice
have been used to engraft the human hematopoietic system to study
hematopoiesis, immunity, inflammatory disease and human-specific
pathogens. This humanized NSG mouse model routinely contains
.25% human CD45+ cells in the peripheral blood 12 weeks post
engraftment of hematopoietic stem cells [35]. Many of the
inflammatory mediators expressed in the current study play an
important role in immune cell recruitment [36,37]. The ability to
engraft human immune cells will allow us to study the effect of these
mediators on specific immune cells populations. Future studies will
make use of the fully humanized lung xenograft model to study the
role of the inflammatory response in the pathogenesis of the
different henipavirus strains in the human lung.
In conclusion, these data confirm that the human lung is highly
susceptible to NiV infection. NiV is capable of replicating to high
titers in the human lung and targets both respiratory epithelium
and endothelium. Infection results in the characteristic syncytial
formation and extensive lung damage. Key inflammatory medi-
ators such as IL-6, IP-10, G-CSF and GM-CSF are expressed
during infection. This model will allow for more detailed studies of
the pathogenesis of respiratory disease caused by henipavirus
infection. Furthermore, these data point to several inflammatory
mediators that potentially play critical roles in henipavirus
pathogenesis, which may be valuable as candidates for future
studies of the mechanism of henipavirus pathogenesis and as
potential targets for treatment.
Materials and Methods
Ethics statement
Approval for animal experiments was obtained from the
Institutional Animal Care and Use Committee, University of
Texas Medical Branch (protocol number 0905041). Animal work
was performed by certified staff in an Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC)
approved facility. Animal housing, care and experimental proto-
cols were in accordance with NIH guidelines of the Office of
Laboratory Animal Welfare. Discarded tissue from deceased
human fetuses was obtained via a non-profit partner (Advanced
Bioscience Resources, Alameda, CA) as approved under exemp-
tion 4 in the HHS regulations (45 CFR Part 46). Need for
informed consent was waived by the UTMB Institutional Review
Board.
Viruses and cells
NiV (Malaysia strain) was kindly provided by the Special
Pathogens Branch of the Centers for Disease Control and
Prevention, Atlanta, Georgia, United States. The virus were
propagated on Vero cells in Dulbecco’s minimal essential medium
supplemented with 10% fetal calf serum (Hyclone, Logan, UT), L-
glutamine, penicillin and streptomycin at 37uC in a humidified
CO2 incubator (5%). All infectious work was performed in a class
II biological safety cabinet in a biosafety level 4 laboratory (BSL4)
at the Galveston National Laboratory.
Human lung xenograft mouse model
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice, also known as
NOD/SCID/ccnull or NSG mice (Jackson Laboratories), 3–5
weeks of age, were housed in a sterile microisolator environment.
Mice were engrafted with human lung tissue (Advanced Bioscience
Resources, Alameda, CA). Six fragments of human fetal lung from
the same donor (15–19 weeks of age) were sutured to muscle fascia
in the dorsal subcutaneous space in each mouse (,0.5 cm from
the spine, three on each side). Animals received appropriate post-
surgery treatment including antibiotics and analgesics.
Animal infection
Twelve weeks post-engraftment, animals were transferred to an
ABSL-4 facility. Prior to infection, animals were anesthetized by
chamber induction (5 Liters/min 100% O2 and 3–5% isoflurane).
Three of the six lung tissues were inoculated via intragraft
injection of 105 TCID50 NiV in a 50 ml volume. Animals were
monitored daily for weight loss and clinical signs. Groups of 3
animals were euthanized on days 1, 3, 5, 7 and 10 post infection,
and samples for virus isolation and histological examination were
procured from whole blood (EDTA vacutainer), human lung
tissues, and mouse liver, spleen, kidney, lung, heart and brain. In a
separate experiment, 2 animals were injected via the intraperito-
neal route with 105 TCID50 NiV and euthanized 10 days post
infection. Control groups were NSG mice without a lung
xenograft and challenged via the intradermal route with 105
TCID50 NiV on the back of the mouse at the same location the
human lung xenografts would be.
Virus titrations
Whole blood was tested for presence of infectious virus by 10-
fold diltutions as described below. Tissue samples were weighed
and homogenized in 10 equivalent volumes of DMEM to generate
a 10% solution. The solution was centrifuged at 10,000 rpm under
aerosol containment in a table top centrifuge for 5 min to pellet
Figure 6. Cytokine levels in Nipah virus infected human lung xenografts. The concentrations of cytokines were determined in lung
homogenates of human lung xenografts following direct infection with NiV as described in the Experimental Procedures. Concentrations are
expressed as picogram (pg) cytokine per gram lung tissue. The error bars represent the standard deviation.
doi:10.1371/journal.ppat.1004063.g006
Nipah Virus Infection in Human Lung
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insoluble parts. Virus titration was performed using a TCID50
assay on 96-well plates (16104 Vero cells per well) with 100 mL
inocula (cleared homogenate or whole blood) from 10-fold serial
dilutions. Plates were incubated for 3 days at 37uC, and wells were
scored for cytopathic effect (CPE). Virus concentrations were
calculated as TCID50 per gram of tissue.
Histopathology and immunohistochemistry
All tissue samples were immersion-fixed in 10% neutral buffered
formalin for at least 7 days under BSL4 conditions. Prior to
removal from the BSL4 laboratory, formalin was changed and
specimens were processed under BSL2 conditions by conventional
methods, either embedded in paraffin, sectioned at 5 mm thickness
and stained with hematoxylin and eosin (H&E) or embedded in
Tissue Tek and frozen sections cut at 3–8 mm thickness and used
for immunofluorescent (IF) staining. Tissues for immunohisto-
chemistry (IHC) were stained as previously described using a
rabbit anti-NiV-nucleoprotein (N) antibody (kindly provided by
Dr. C. Broder, Uniformed Services University, Bethesda, MD)
[13]. Tissues for IF were stained with a rabbit anti-NiV-N
antibody, a biotinylated anti-CD31 (eBioscience), anti-collagen IV
labeled with Alexa 647 (eBioscience), anti ephrin B2 (Santa Cruz
Biotechnology) or ephrin B3 (R&D Systems) and Hoechst for
nuclear staining. NiV N in mouse tissue could only be detected
following immunofluorescent staining, likely due to the limit of
detection by conventional IHC. An Alexa 546 labeled secondary
antibody (Life Technologies) was used for detection of the anti
NiV N antibody as well as anti ephrin B2 and B3 antibodies and
an Alexa 488 conjugated streptavidin (R&D Systems) was used for
detection of the anti-CD31 antibody.
Milliplex analysis
Cytokine/chemokine concentrations in the homogenates of NiV
infected human lung tissues were determined using a Milliplex
Human Cytokine PREMIXED 28 Plex Immunoassay Kit
(Millipore, Billerica, USA). Prior analysis, samples were inactivat-
ed on dry ice by gamma-radiation (5 MRad). The assay was
performed according to the manufacturer’s instructions. The
concentration of the following 28 cytokines were determined using
the Bio-Plex 200 system (BioRad): Epidermal Growth Factor
(EGF), Granulocyte-Colony Stimulating Factor (G-CSF), Granu-
locyte Macrophage-Colony Stimulating Factor (GM-CSF), inter-
feron (IFN)-a2, IFNc, Interleukin (IL)-1a, IL-1ß, IL-2, IL-3, IL-4,
IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15,
IL-17A, chemokine ligand 3-like 1 (CCL3L1 or MIP-1a),
chemokine ligand 4 (CCL4 or MIP-1ß), chemokine ligand 10
(IP-10 or CXCL10), chemokine ligand 11 (CCL11 or Eotaxin-1),
chemokine ligand 13 (CCL13 or MCP-1), Tumor Necrosis Factor
(TNF-a), Lymphotoxin alpha (TNFß) and Vascular Endothelial
Growth Factor A (VEGF).
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